October 29, 2020 07:00 AM EDT

Arcus and AstraZeneca partner on a high stakes anti-TIGIT/PD-L1 PhIII cancer study, looking to improve on a standard of care

John Carroll

Editor & Founder

For AstraZeneca, the PACIFIC trial in Stage III non-small cell lung cancer remains one of the big triumphs for AstraZeneca’s oncology R&D group. It not …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Arcus and AstraZeneca partner on a high stakes anti-TIGIT/PD-L1 PhIII cancer study, looking to improve on a standard of care

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Federal appeals court says Teva must delist Orange Book inhaler patents

Ar­cus and As­traZeneca part­ner on a high stakes an­ti-TIG­IT/PD-L1 PhI­II can­cer study, look­ing to im­prove on a stan­dard of care

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

Arcus and AstraZeneca partner on a high stakes anti-TIGIT/PD-L1 PhIII cancer study, looking to improve on a standard of care

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Federal appeals court says Teva must delist Orange Book inhaler patents